Repurposing Ivacaftor for treatment of Staphylococcus aureus infections.

Abstract

Drug repurposing of non-antimicrobials is a novel method to augment a seriously depleted drug pipeline for targeting drug-resistant pathogens. This article highlights the potent antimicrobial activity of Ivacaftor against Staphylococcus aureus, including vancomycin- and other multidrug-resistant strains. The potent activity of Ivacaftor in vivo is also demonstrated in a murine neutropenic thigh infection model. Taken together, these results support the potential of Ivacaftor as an antimicrobial agent for the treatment of staphylococcal infections.

• Authors: Ritesh Thakare, Alok Kumar Singh, Swetarka Das, N Vasudevan, Gorakhnath R Jachak, D Srinivasa Reddy, Arunava Dasgupta, Sidharth Chopra
• Journal: International journal of antimicrobial agents (Int J Antimicrob Agents) Vol. 50 Issue 3 Pg. 389-392 (Sep 2017) ISSN: 1872-7913 [Electronic] Netherlands
• PMID: 28694231 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Chemical References

• Aminophenols
• Anti-Bacterial Agents
• Chloride Channel Agonists
• Quinolones
• ivacaftor

Topics

• Aminophenols (administration & dosage, pharmacology)
• Animals
• Anti-Bacterial Agents (administration & dosage, pharmacology)
• Chloride Channel Agonists (administration & dosage, pharmacology)
• Disease Models, Animal
• Drug Repositioning
• Mice, Inbred BALB C
• Quinolones (administration & dosage, pharmacology)
• Staphylococcal Infections (drug therapy)
• Staphylococcus aureus (drug effects)
• Treatment Outcome